Business Wire

Egress, a KnowBe4 Company, Named a Leader in Gartner® First Magic Quadrant™ for Email Security Platforms

Share

Egress, a KnowBe4 company, recognized for its Ability to Execute and Completeness of Vision in the 2024 Magic Quadrant for Email Security Platforms

Egress, a KnowBe4 company, the first provider of adaptive AI-enabled email security, today announced it has been recognized as a Leader in 2024 Gartner Magic Quadrant for Email Security Platforms. Egress has been recognized for its Ability to Execute and Completeness of Vision in this report.

We see a recent rise of advanced technology to address sophisticated inbound phishing attacks and behavior-led outbound data breaches has driven significant innovation in email security.

Egress is proud to be a Leader in the first Magic Quadrant for Email Security Platforms. We believe Egress has architected an adaptive AI-enabled platform to detect the full spectrum of inbound and outbound threats. Egress believes we are recognized because of our:

  • Advanced AI-enabled detection to mitigate the full spectrum of threats
  • Holistic understanding of human risk generated through deep per-user behavioral analytics and threat intelligence, used to deliver personalized security at the point of risk
  • Offering the first adaptive security architecture for cloud email
  • Delivering continuous behavioral-based training through real-time nudges

Egress’ positioning in the Magic Quadrant follows its acquisition earlier this year by KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management. Together, Egress and KnowBe4 provide customers with a seamless integration that leverages email threat intelligence to automate personalized training and phishing simulations based on real-time cybersecurity threats. By acquiring Egress, KnowBe4 will deliver a single AI-powered and adaptive human risk management platform.

Commenting on the announcement, Egress CEO Tony Pepper stated: “We’re delighted to be named a Leader in the 2024 Gartner Magic Quadrant for Email Security Platforms. Email is the primary threat vector for organizations globally and we feel Egress has played an influential role in bringing adaptive AI-enabled technology to the market to prevent a broader array of threats and deliver positive outcomes for customers. It’s an exciting time to be part of the email security market and I look forward to working closely with the KnowBe4 team to help our customers effectively address the problem of human risk holistically.”

Download a copy of the report.

Gartner, Magic Quadrant for Email Security Platforms, 16 December 2024, Max Taggett, Nikul Patel, Franz Hinner, Deepak Mishra

GARTNER is a registered trademark and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Egress, a KnowBe4 Company

As advanced persistent threats continue to evolve, we recognize that people are the biggest risk to organizations’ security and are most vulnerable when using email.

Egress is the only cloud email security platform to continuously assess human risk and dynamically adapt policy controls, preparing customers to defend against advanced phishing attacks and outbound data breaches before they happen. Leveraging contextual machine learning and neural networks, with seamless integration using cloud-native API architecture, Egress provides enhanced email protection, deep visibility into human risk, and instant time to value.

www.egress.com

About KnowBe4

KnowBe4 empowers workforces to make smarter security decisions every day. Trusted by over 70,000 organizations worldwide, KnowBe4 helps to strengthen security culture and manage human risk. KnowBe4 offers a comprehensive AI-driven ‘best-of-suite’ platform for Human Risk Management, creating an adaptive defense layer that fortifies user behavior against the latest cybersecurity threats. The HRM+ platform includes modules for awareness & compliance training, cloud email security, real-time coaching, crowdsourced anti-phishing, AI Defense Agents, and more. As the only global security platform of its kind, KnowBe4 utilizes personalized and relevant cybersecurity protection content, tools and techniques to mobilize workforces to transform from the largest attack surface to an organization’s biggest asset.

www.knowbe4.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241219252247/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release

Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release

Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release

Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release

Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye